Search results
Results from the WOW.Com Content Network
Methylhexanamine (also known as methylhexamine, 1,3-dimethylamylamine, 1,3-DMAA, dimethylamylamine, and DMAA; trade names Forthane and Geranamine) is an indirect sympathomimetic drug invented and developed by Eli Lilly and Company and marketed as an inhaled nasal decongestant from 1948 until it was voluntarily withdrawn from the market in the 1980s.
Ecopipam is currently in a Phase 3 clinical trial for the treatment of Tourette syndrome in children ages 7 to 17 [18] and for the treatment of restless syndrome augmentation (Phase 1/2) [2] Ecopipam is an investigational first-in-class drug also being evaluated for the treatment of childhood-onset fluency disorder ( stuttering ) in adults. [ 19 ]
It is a colorless liquid, although, like many amines, samples are often colored due to contaminants. It has a fishy odor and is miscible with water. Like other amines, it is a weak base , compared to strong bases such as NaOH , but it is a stronger base than its aromatic analog, aniline .
Hexylamine or n-hexylamine is a chemical compound with the formula CH 3 CH 2 CH 2 CH 2 CH 2 CH 2 NH 2. This colorless liquid is one of the isomeric amines of hexane. At standard temperature and pressure, it has the ammonia/bleach odor common to amines and is soluble in almost all organic solvents.
H 2 C=CH 2 + HCl → CH 3 CH 2 Cl. In oxychlorination, hydrogen chloride instead of the more expensive chlorine is used for the same purpose: CH 2 =CH 2 + 2 HCl + 1 ⁄ 2 O 2 → ClCH 2 CH 2 Cl + H 2 O. Secondary and tertiary alcohols react with hydrogen chloride to give the corresponding chlorides.
[3] [4] Hence, 3-CC shows almost 10-fold preference for induction of dopamine release over serotonin release and around 1.5-fold preference for induction of dopamine release over norepinephrine release. [3] [4] The drug was encountered as a novel designer and recreational drug by 2020. [1]
3-Chloro-PCP (3'-Cl-PCP) is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It has comparable potency to phencyclidine but with a slightly different effects profile, being somewhat more potent as an NMDA antagonist but around the same potency as a dopamine reuptake inhibitor . [ 1 ]
Sodamide alkylation of phenothiazine (1) with 1-bromo-3-chloro-2-methylpropane [6974-77-2] (2) gives 10-(3-Chloro-2-methylpropyl)phenothiazine, CID:12299119 (3). Completion of the sidechain by alkylation with 1-[2-(2-Hydroxyethoxy) Ethyl]Piperazine [13349-82-1] ( 4 ) and displacement of the halogen completes the synthesis of Dixyrazine ( 5 ).